Gray matter imaging in multiple sclerosis: what have we learned?

1471-2377-11-153 1471-2377 Review Gray matter imaging in multiple sclerosis: what have we learned? HulstEHannekehe.hulst@vumc.nl GeurtsJGJeroenj.geurts@vumc.nl

Department of Radiology, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

Department of Anatomy and Neurosciences, section of Clinical Neuroscience, VU University Medical Centre, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

BMC Neurology 1471-2377 2011 11 1 153 http://www.biomedcentral.com/1471-2377/11/153 10.1186/1471-2377-11-15322152037 1010201112122011121220112011Hulst and Geurts; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

At the early onset of the 20^thcentury, several studies already reported that the gray matter was implicated in the histopathology of multiple sclerosis (MS). However, as white matter pathology long received predominant attention in this disease, and histological staining techniques for detecting myelin in the gray matter were suboptimal, it was not until the beginning of the 21^stcentury that the true extent and importance of gray matter pathology in MS was finally recognized. Gray matter damage was shown to be frequent and extensive, and more pronounced in the progressive disease phases. Several studies subsequently demonstrated that the histopathology of gray matter lesions differs from that of white matter lesions. Unfortunately, imaging of pathology in gray matter structures proved to be difficult, especially when using conventional magnetic resonance imaging (MRI) techniques. However, with the recent introduction of several more advanced MRI techniques, the detection of cortical and subcortical damage in MS has considerably improved. This has important consequences for studying the clinical correlates of gray matter damage. In this review, we provide an overview of what has been learned about imaging of gray matter damage in MS, and offer a brief perspective with regards to future developments in this field.

Background

For many years, focal inflammatory demyelination in the white matter (WM) was considered the most important pathological 'hallmark' of multiple sclerosis (MS). However, demyelination in the cerebral cortex was already observed in early pathology studies by Sander (1898), Dinkler (1904), Schob (1907) and Dawson (1916) 1234. After these initial, largely casuistic, descriptions of demyelination in the gray matter (GM) of MS patients, the topic was largely disregarded. This was mostly due to difficulties involved with the visualization of cortical GM lesions in the post mortem setting, in which conventional histochemical staining procedures were applied, as well as to a predominant attention for the generally more conspicuous process of inflammatory WM demyelination.

However, by the start of the 21^stcentury, the focus within MS research slowly shifted back from WM to GM. In 2003, when new immunohistochemical staining techniques that improved the ex vivo detection of GM damage had become available, the presence and extent of GM demyelination was described in detail and pathophysiological processes causing GM damage, as well as its visualization with modern magnetic resonance imaging (MRI) techniques, became central issues in MS research (see Figure 1).

Figure 1

Timeline of GM imaging in MS

Timeline of GM imaging in MS. A schematic overview of developments in the field of GM imaging in MS from the beginning of the 20^thcentury until now. A, B, D) Reproduced from Kidd et al. 7, Kutzelnigg et al. 19, and Schmierer et al. 88 respectively, all with permission from Oxford University Press. C) Reproduced from Cifelli et al. 100 with permission from John Wiley and Sons. E, F) Reproduced from Geurts et al. 69 and Roosendaal et al. 126 respectively, both with permission of the Radiological Society of North America.

This review will focus on what has been learned in the past decade of imaging GM pathology in MS. As will be shown, visualization of GM demyelination was difficult at first, but improved upon technical developments in the field. An important question that now remains is whether MRI visualization of GM pathology in MS is sufficient, or whether further improvement is still needed.

GM involvement in a WM disease

After the first pivotal reports of GM damage in MS in the early 20th century, it was not until 1962 that Brownell and Hughes reported that 26% of the macroscopically visible lesions found in their post mortem material of 22 MS patients were (partly) located in or around the cortical and subcortical GM 5. Extensive involvement of the cortex in MS patients was later confirmed in histopathology 6 and in a study combining post mortem MRI and conventional histology 7.

At that point in time, the detection of GM demyelination in tissue sections was difficult, as standard histochemical myelin stains like luxol fast blue (LFB) were not sufficiently adequate for visualization of changes in GM myelin density. Detection of GM pathology with conventional T2-weighted MRI also proved to be difficult because of the intrinsically low myelin density in the cortex, which generates little contrast between normal GM and demyelinated GM lesions, and because of the fact that cortical lesions may be small and partial volume effects with cerebrospinal fluid in the sulci can interfere with reliable lesion detection 78. To improve the detection of cortical lesions on MRI, newer techniques like fast fluid-attenuated inversion recovery (FLAIR) MR sequence were used 910. FLAIR improved lesion detection in the cortex and in (juxta)cortical areas as compared to conventional T2-weighted MRI 91011121314. However, the reported prevalence of cortical lesions on MRI was still much lower than that reported in post mortem studies 10.

Description and classification of GM pathology in MS

Histopathological detection of intracortical MS lesions improved with the use of myelin protein immunohistochemistry in the beginning of the 21^stcentury. Using immunohistochemistry for myelin basic protein (MBP) and proteolipid protein (PLP), Bö and colleagues shed more definitive light on the extent and distribution of cortical demyelination in MS 1516. In chronic MS cases myelin loss was found in 26.5% of their systematically examined areas of cerebral cortex 15. The investigators proposed a classification system for cortical lesions which distinguished four different cortical lesion types: the mixed GM-WM (type I) lesions and the purely cortical (type II, III, and IV) lesions 16 (see Figure 2).

Figure 2

Pathological classification system of GM lesions in MS

Pathological classification system of GM lesions in MS. GM lesion classification system as proposed by Bo et al,. 2003. Type 1 lesions (A) extend through both white and gray matter. Type 2 lesions (B) are intracortical, having no contact with white matter or with the surface of the brain. Type 3 lesions (C) extend inward from the surface of the brain. Type 4 lesions (D) extend through the whole width of the cortex without reaching into white matter. Reproduced from Geurts and Barkhof 131 with permission from Elsevier.

The pathology of GM lesions generally differs considerably from that of WM lesions. Lymphocyte infiltration, complement deposition, and blood-brain-barrier disruption have not been detected in GM lesions, whereas WM lesions are known to harvest substantial inflammation 161718. Another pivotal study by Kutzelnigg and colleagues showed demyelination of the MS cortex and reported extreme cases with more than 70% of cortical demyelination 19. Besides demyelination in the cerebral cortex, demyelination was later also found in the cerebellum 20, in deep gray matter structures 2122, and in the GM of the spinal cord 23.

Pathological studies demonstrated that cortical demyelination is most frequent and extensive in patients with a longer disease duration (secondary progressive MS; SPMS) and with a more progressive form of MS (primary progressive MS, PPMS), whereas it was found to be rare in relapsing remitting MS patients (RRMS) 1921. However, GM demyelination was recently found in biopsy material of an early MS patient, even before disseminated WM lesions on MRI became visible 24.

Although histopathological studies had improved as a result of the new staining methods, GM lesions remained extremely difficult to detect on conventional MRI. For example, it was shown that T2-weighted and FLAIR imaging detected only 3 to 5% of a total of 63 histopathologically defined cortical lesions 25. Nevertheless, the (juxta)cortical lesions that were detected with these MRI sequences were clearly associated with cognitive impairment, epilepsy, depression, fatigue, and physical disability in MS patients 26272829303132.

In parallel, MRI studies focused on imaging the normal appearing GM of MS patients (NAGM; i.e., GM that looks normal on conventional T2-weighted MRI, but might nevertheless be histopathologically abnormal) using more advanced, quantitative MRI techniques. These techniques are generally more sensitive to (subtle) pathology in the GM than conventional MRI sequences 33. Clinically relevant abnormalities in the NAGM of MS patients were reported with magnetization transfer imaging (MTI) 34353637, T1-relaxometry 3839, diffusion tensor imaging (DTI) 4041, and proton magnetic resonance spectroscopy (MRS) 424344 in both cortical and subcortical GM areas in MS. These measured abnormalities most likely reflect subtle tissue changes due to lesions or independent from lesions.

To sum up, around the turn of the century, GM pathology in MS became increasingly recognized as an important pathological hallmark in this 'typical' WM disease. The introduction of new histopathological staining methods improved the visualization of GM damage and revealed that GM demyelination was frequent, widespread, and more extensive in patients with longer disease duration. The pathological substrate of GM lesions was found to be different from WM lesions, as GM lesions are largely non-inflammatory. On conventional MRI, only a minority of GM lesions could initially be visualized. However, these lesions were associated with clinical deterioration. Besides cortical lesions, quantitative MRI also demonstrated clinically relevant abnormalities in the NAGM of MS patients.

GM atrophy and cortical thinning

Whereas the detection of focal GM lesions was difficult using conventional MRI measures, GM atrophy measurements proved to be robust and reliable using standard MRI sequences 33. Automated methods to estimate brain volume were reproducible, both within and between research centres 4546. Decreased GM tissue volume, as well as cortical thinning, were found in MS patients compared to healthy age-matched controls and were observed already early in the disease course and across different MS types 47484950515253545556575859. In a longitudinal study it was shown that whole brain atrophy rates were similar over time in stable Clinically Isolated Syndrome (CIS) patients, but steadily increasing as diseased severity increased (RRMS and SPMS) 60. Interestingly, a significant and disproportionate increase in GM atrophy occurs in MS patients in more advanced disease stages 5561, while WM atrophy rates accumulate more constantly over time 60. GM atrophy and cortical thinning were significantly associated with physical disability and cognitive decline 4748495055566263646566, and importantly, measures of GM atrophy showed stronger correlations with clinical parameters than WM damage 56606166.

New imaging techniques to detect cortical GM lesions

In 1994, a new MRI sequence, the double inversion recovery (DIR), was introduced. This technique provided excellent distinction between the cerebral cortex and the WM in the healthy human subjects by suppression of the signal from WM and the cerebrospinal fluid (CSF) 67. DIR proved to be superior in comparison to FLAIR where it concerned intratentorial lesions and lesions with low contrast on T2-weighted MR sequences 68. However, it was not until several years later that DIR was applied to image GM pathology in MS 69. In 2005, MR imaging with a 3D DIR sequence demonstrated increased intracortical lesion detection in the MS brain, as well as improved distinction between juxtacortical and mixed WM-GM lesions. A relative gain of 152% of DIR over FLAIR was described in the detection of cortical lesions 69. Using DIR at a higher field strength (3T) led to an even further increase of detected cortical lesions in MS patients 70.

A series of important scientific contributions by Calabrese and colleagues subsequently confirmed histopathology studies by reporting that intracortical lesions detected on DIR are already present early in the disease 71727374 and are found in both relapse-onset and PPMS patients 7475. The investigators further showed that cortical lesions are most frequently found in SPMS patients, in patients of the male sex, and in patients who also had IgG oligoclonal bands in the CSF 7677. A relative sparing of the cortex was found for patients with benign MS 72. The presence of cortical lesions was associated with clinical disability, brain volume loss and/or cognitive impairment 737576777879. Longitudinal DIR studies showed an increase in cortical lesion number and/or an increase in lesion size over time 73757780.

These results notwithstanding, the use of different DIR sequences and different lesion scoring criteria in different research centres made the comparison of available cortical lesion data in the literature challenging. Therefore, in an attempt to improve consistency of cortical lesion scoring between raters and centres using DIR, international cortical lesion scoring guidelines were proposed 8182. These DIR scoring guidelines were subsequently verified in the post mortem setting and showed that although DIR is highly pathologically specific (90% of cortical hyperintensities identified related to actual lesions in post mortem tissue), the sensitivity of DIR is rather poor 82. Especially subpial cortical lesions were found to be difficult to detect on DIR.

So far, no specific pathological properties were found that determine whether cortical lesions become MRI-visible or MRI-invisible. Instead, it was shown that the visibility of cortical lesions on MRI is predominantly determined by their size. Furthermore, MRI-visible cortical lesions were strongly associated with a higher total cortical lesion load in brain tissue specimens, which suggests that when cortical lesions become visible on MRI, they merely reflect 'the tip of the pathological iceberg' 83.

Other studies aiming to improve visualization of cortical GM lesions used phase-sensitive inversion recovery (PSIR) and 3D T1 weighted sequences 8485. Future post mortem work will have to show whether sensitivity and specificity for cortical GM lesions may further improve when combinations of T1-based techniques, PSIR and DIR are used, when compared to DIR alone. Ideally, this would lead to a recommendation as to which (combination of) technique(s) should be used to optimally visualize (cortical) GM pathology in vivo, and further increase our understanding about the role of GM damage in clinicocognitive deterioration in MS.

High-field and ultrahigh-field MRI

With the introduction of (ultra) high-field MRI, signal-to-noise ratio, spatial resolution, and image contrast improved, which all benefited the detection of GM lesions 868788. In vivo studies using 2D T2*-weighted gradient-echo and 3D T1-weighted magnetization-prepared rapid-acquisition GRE sequences at 7T or higher were able to provide high-resolution anatomical images of cortical lesions 899091. It was recommended that a combination of MR sequences be used at higher field strength, as different techniques may provide complementary information in the definition of cortical lesions 92. Furthermore, and this is new when compared to standard field, it was shown that ultra high-field MRI enables accurate visualization of subpial GM lesions 158891.

Non-neocortical GM damage

MRI and histopathology studies showed that atrophy and demyelinated lesions do not only exist in the cortical GM but also in other GM structures such as the thalamus, hippocampus, caudaute, putamen, pallidum, claustrum, hypothalamus, amygdala and substantia nigra 2122234293949596979899100101102103104105, see Figure 3. Hypothalamic lesions were found to be numerous in a post mortem MS dataset 96 and higher inflammatory activity of hypothalamic lesions was associated with a worse disease course 97.

Figure 3

Subcortical GM damage in MS

Subcortical GM damage in MS. Subcortical atrophy, measured using FIRST (part of FSL 4.1: http://www.fmrib.ox.ac.uk/fsl/). Above: Effect sizes of subcortical atrophy in a cohort of 120 early RRMS patients, six years post-diagnosis. Below: Two examples of segmented subcortical structures in a healthy control (HC, above) and an age-matched RRMS patient (MS, below).

Of all the GM structures, the thalamus has been studied most extensively with MRI 21224299100101102103104105106107108109110. One of the reasons that the thalamus received broad attention is because of the extensive reciprocal connections with the cortex and subcortical structures which makes this brain structure particularly sensitive to pathological changes in other areas of the brain 100. Several studies focused on the volume of non-neocortical GM structures and showed thalamic atrophy in all different MS disease types 102103104106107108109111112113 (see Figure 3). In CIS patients, thalamic atrophy was already present 103104108112, and interestingly a reduction in thalamic fraction was more pronounced in RRMS patients compared to SPMS patients 104. Additionally, in a longitudinal study thalamic atrophy was found to be more pronounced in RRMS patients compared to regional cortical atrophy 111. This indicates that neuronal damage in the thalamus occurs early in the disease course. In terms of clinical relevance, thalamic atrophy has been associated with disability, cognitive impairment, and fatigue 99104107110. Furthermore, thalamic atrophy was seen in paediatric MS patients and PPMS patients as well 109113114. Using quantitative MR techniques, changes in the chemical composition of thalamic tissue could be detected. A reduction of N-acetylaspartate (NAA) in the thalamus was found with MRS and is thought to reflect neuro-axonal loss 42100102. MTI showed a reduced magnetization transfer ratio (MTR) in the thalamus, an abnormality which was already found within the first five years of the disease 101104. And also changes in thalamic DTI measures were partly associated with disability, brain volume, and lesion load 105.

The hippocampus was found to be a predilection site for GM demyelination in MS 2195115. In vivo, areas of signal abnormality in the hippocampus were also identified by using DIR 116, as well as increased levels of myo-inositol using MRS 42. In addition, hippocampal atrophy was found in RRMS, SPMS, and PPMS patients, imaged at 1.5T and 3T 117118. At 3T, atrophy was reported to start in the cornu ammonis 1 (CA1) region of the hippocampus in RRMS, only to expand to other CA regions in more advanced stages of the disease (SPMS) 118.

Besides structural differences in the MS brain, functional changes can be studied as well by using e.g. functional MRI (fMRI). Different cognitive paradigms for task-fMRI have been used so far, as well as resting-state fMRI. Several differences between healthy controls and MS patients were found in terms of brain activation and brain connectivity 119120121122123124125. Some fMRI studies focused on a particular GM brain structure or functional anatomical system rather than on a specific cognitive domain. For example, reduced functional connectivity was reported between the hippocampus and its anatomical input c.q. target areas, including the anterior cingulate gyrus, thalamus, and prefrontal cortex. These changes were more pronounced in MS patients with hippocampal atrophy, but were also detected in patients without hippocampal volume loss 126. Additionally, in a task-specific fMRI study, differences in hippocampal function during a memory encoding task were detected between MS patients with and MS patients without cognitive decline. These findings were independent of differences in hippocampal volume and number of hippocampal lesions 127 (see Figure 4).

Figure 4

Non-neocortical GM damage: the hippocampus

Non-neocortical GM damage: the hippocampus. A) Extensive hippocampal demyelination observed in post-mortem material. Reproduced from Geurts et al. 95 with permission from the American Association of Neuropathologists Inc. B) In vivo detection of hippocampal lesions using DIR imaging. Reproduced from Roosendaal et al. 116 with permission from John Wiley and Sons. C) Hippocampal atrophy on high field MRI provides detailed information on the specific location in the hippocampus where atrophy is present. Reproduced from Sicotte et al. 118 with permission from Oxford University Press. D) Anno 2011 it is besides structural changes also possible to study functional changes in the hippocampus; the blue areas indicates reduced hippocampal activity in cognitively impaired MS patients compared to healthy controls. Reproduced from Hulst et al. 127 with permission from John Wiley and Sons.

To summarize, during the past few years, the number of studies investigating GM damage in MS has tremendously increased. GM atrophy and cortical thinning were shown to be robust and reliable measures. GM atrophy correlated more strongly than WM atrophy with disability and cognitive impairment. New imaging techniques, such as DIR, improved the detection of cortical lesions in vivo. With the introduction of (ultra) high-field MRI, the visualization of cortical lesions improved even further. Recently published international consensus guidelines for scoring cortical lesions on DIR will likely increase the consistency between different research groups, and will improve the comparability of different DIR studies. Post mortem work demonstrated that DIR is pathologically specific, but lacks sensitivity. This means that many cortical lesions are still missed and MRI detects only 'the tip of the pathological iceberg'. Despite their under representation on MRI, cortical lesions were shown to be clinically relevant. Both imaging and histopathology studies showed that GM damage in MS is not limited to the neocortex; the cerebellum, spinal cord, and non-neocortical GM structures are affected as well.

A brief future perspective of GM imaging in MS

From a pathological point of view, it is clear that GM damage is common, widespread, and different from WM damage. A challenging next step is to investigate the cause(s) of GM pathology. For example, whether damage to the GM develops purely as a result of inflammatory demyelination in the WM or whether pathological processes in these two compartments of the brain are less connected than formerly thought, still remains to be elucidated 128129130.

As discussed in this review, from the neuroimaging perspective, MRI techniques have substantially improved over the past years and several new imaging modalities to better detect GM abnormalities are now available. It is possible to visualize cortical lesions with DIR, T1-based or phase-sensitive sequences, as well as with (ultra) high-field MRI. Moreover, GM tissue loss can be reliably measured with the help of conventional MR sequences, and more subtle tissue changes can be observed with quantitative MRI. Finally, the function of specific GM structures or functional systems, as well as functional and structural connectivity changes within the brain can be imaged with MRI. With all these different imaging techniques to visualize GM pathology in vivo, it now remains to be determined which image modality, or combination of imaging modalities, best explains or predicts clinical symptomatology, and whether these techniques can be reliably used to monitor future treatment effects. Furthermore, the spatiotemporal relation between structural and functional changes, as well as changes in network dynamics in the brain as a consequence of disease will be difficult but exciting topics for future research in this field. The past few years of GM imaging research have seen tremendous progress; with the knowledge and technology now available, it is likely that ongoing joint efforts between different fields of research will create an even greater understanding of the role of GM pathology in MS in the near future.

Conclusions

What have we learned in GM imaging in MS?

▪ GM damage in MS is common and widespread, especially in chronic MS;

▪ The underlying pathological correlates of GM damage in MS are different from WM damage;

▪ GM pathology is present in all stages of the disease, but is more prominent in SPMS and PPMS compared to RRMS;

▪ Although a relatively non-specific measure of overall pathology, GM atrophy measurements are reliable and robust and correlate strongly with disability and cognitive impairment (more so than WM atrophy);

▪ Cortical lesions are of clinical relevance and are associated with a worse physical and cognitive performance;

▪ Cortical lesions have been difficult to visualize with conventional MRI, but due to newer imaging techniques (like DIR) lesion detection improved;

▪ Post mortem DIR verification showed high specificity of DIR lesions and increased sensitivity compared to conventional MR sequences; however, a substantial number of cortical lesions is still missed with in vivo MRI;

▪ International consensus guidelines on DIR cortical lesion scoring will likely improve the comparability of different DIR studies;

▪ (Ultra) high-field MRI holds promise for more precise detection of cortical lesions, with maybe even the possibility to categorize GM lesions in vivo according to the pathological classification system used post mortem; especially the detection of subpial lesions (type III lesions) is likely to benefit from the use of (ultra) high-field MR imaging;

▪ Non-neocortical GM damage is frequently detected in histopathological studies as well as on MRI. Thalamic and hippocampal abnormalities have been studied most extensively and were shown to correlate with clinical parameters;

▪ Besides structural changes in the GM of MS patients, functional changes can be detected as well by using fMRI; this should shed more light on the relationship between functional and structural changes in the MS brain in future studies.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HEH and JJGG participated in the preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank the Dutch MS Research Foundation for supporting HEH (grant numbers: 02-358b, 08-648) and we thank Menno M. Schoonheim for providing Figure 3.

Hirnrindenbefunde bei multipler SkleroseSanderMMonatschrift Psychiatrie Neurol1898IV427436Ein Beitrag zur patologischen Anatomie der multiplen SkleroseSchobFMonatschrift Psychiatrie Neurol190722628710.1159/000211848Zur Kasuistik der multiplen Herdsklerose des Gehirns und RuckenmarksDinklerMDeuts Zeits f Nervenheilk19042623324710.1007/BF01667829The Histology of Multiple SclerosisDawsonJWTrans R Soc Edinburgh191650517740The distribution of plaques in the cerebrum in multiple sclerosisBrownellBHughesJTJ Neurol Neurosurg Psychiatry19622531532010.1136/jnnp.25.4.31549547014016083The neuropathology of multiple sclerosisLumsdenCEHandbook of clinical neurologyAmsterdam, North-HollandVinken PJ, Bruyn GW1970217309Cortical lesions in multiple sclerosisKiddDBarkhofFMcConnellRAlgraPRAllenIVReveszTBrain1999122Pt 1172610050891Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissueNewcombeJHawkinsCPHendersonCLPatelHAWoodroofeMNHayesGMCuznerMLMacManusDdu BoulayEPMcDonaldWIBrain1991114Pt 2101310232043938Sensitivity and reproducibility of fast-FLAIR, FSE, and TGSE sequences for the MRI assessment of brain lesion load in multiple sclerosis: a preliminary studyRovarisMYousryTCaloriGFeslGVoltzRFilippiMJ Neuroimaging19977981029128448Cortical plaques visualised by fluid-attenuated inversion recovery imaging in relapsing multiple sclerosisBoggildMDWilliamsRHaqNHawkinsCPNeuroradiology199638Suppl 1S10S138811672Multiple sclerosis lesion detection in the brain: a comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echoGawne-CainMLO'RiordanJIThompsonAJMoseleyIFMillerDHNeurology1997493643709270563Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recoveryFilippiMYousryTBarattiCHorsfieldMAMammiSBeckerCVoltzRSpulerSCampiAReiserMFComiGBrain1996119Pt 4134913558813296The sensitivity of thin-slice fast spin echo, fast FLAIR and gadolinium-enhanced T1-weighted MRI sequences in detecting new lesion activity in multiple sclerosisTubridyNMolyneuxPDMoseleyIFMillerDHJ Neurol19992461181118510.1007/s00415005054010653313Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesionsBakshiRAriyaratanaSBenedictRHJacobsLArch Neurol20015874274810.1001/archneur.58.5.74211346369Subpial demyelination in the cerebral cortex of multiple sclerosis patientsBoLVedelerCANylandHITrappBDMorkSJJ Neuropathol Exp Neurol20036272373212901699Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltrationBoLVedelerCANylandHTrappBDMorkSJMult Scler2003932333110.1191/1352458503ms917oa12926836The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesionsBrinkBPVeerhuisRBreijECvan dVDijkstraCDBoLJ Neuropathol Exp Neurol20056414715515751229The blood-brain barrier in cortical multiple sclerosis lesionsvan HorssenJBrinkBPde VriesHEvan dVBoLJ Neuropathol Exp Neurol20076632132810.1097/nen.0b013e318040b2de17413323Cortical demyelination and diffuse white matter injury in multiple sclerosisKutzelniggALucchinettiCFStadelmannCBruckWRauschkaHBergmannMSchmidbauerMParisiJELassmannHBrain20051282705271210.1093/brain/awh64116230320Widespread demyelination in the cerebellar cortex in multiple sclerosisKutzelniggAFaber-RodJCBauerJLucchinettiCFSorensenPSLaursenHStadelmannCBruckWRauschkaHSchmidbauerMLassmannHBrain Pathol200717384410.1111/j.1750-3639.2006.00041.x17493036Grey matter pathology in multiple sclerosisVercellinoMPlanoFVottaBMutaniRGiordanaMTCavallaPJ Neuropathol Exp Neurol2005641101110710.1097/01.jnen.0000190067.20935.4216319720Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matterVercellinoMMaseraSLorenzattiMCondelloCMerolaAMattiodaATriboloACapelloEMancardiGLMutaniRGiordanaMTCavallaPJ Neuropathol Exp Neurol20096848950210.1097/NEN.0b013e3181a19a5a19525897Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cordGilmoreCPDonaldsonIBoLOwensTLoweJEvangelouNJ Neurol Neurosurg Psychiatry20098018218710.1136/jnnp.2008.14876718829630A case of multiple sclerosis presenting with inflammatory cortical demyelinationPopescuBFBunyanRFParisiJERansohoffRMLucchinettiCFNeurology2011761705171010.1212/WNL.0b013e31821a44f121576686Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathologyGeurtsJJBoLPouwelsPJCastelijnsJAPolmanCHBarkhofFAJNR Am J Neuroradiol20052657257715760868Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patientsChristodoulouCKruppLBLiangZHuangWMelvillePRoqueCScherlWFMorganTMacAllisterWSLiLTudoricaLALiXRochePPeysterRNeurology2003601793179812796533Structural brain abnormalities in multiple sclerosis patients with major depressionFeinsteinARoyPLobaughNFeinsteinKO'ConnorPBlackSNeurology20046258659014981175Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIRLazeronRHLangdonDWFilippiMvan WaesbergheJHStevensonVLBoringaJBOriggiDThompsonAJFalautanoMPolmanCHBarkhofFMult Scler2000628028510962549Memory dysfunction in multiple sclerosis corresponds to juxtacortical lesion load on fast fluid-attenuated inversion-recovery MR imagesMoriartyDMBlackshawAJTalbotPRGriffithsHLSnowdenJSHillierVFCapenerSLaittRDJacksonAAJNR Am J Neuroradiol1999201956196210588125Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosisRovarisMFilippiMMinicucciLIannucciGSantuccioGPossaFComiGAJNR Am J Neuroradiol20002140240810696031Seizures in multiple sclerosisSokicDVStojsavljevicNDrulovicJDujmovicIMesarosSErcegovacMPericVDragutinovicGLevicZEpilepsia200142727911207788Epileptic and non-epileptic seizures in multiple sclerosisSpattJChaixRMamoliBJ Neurol20012482910.1007/s00415017026211266015Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevanceMillerDHBarkhofFFrankJAParkerGJThompsonAJBrain20021251676169510.1093/brain/awf17712135961Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosisCercignaniMBozzaliMIannucciGComiGFilippiMJ Neurol Neurosurg Psychiatry20017031131710.1136/jnnp.70.3.311173728311181851Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosisDaviesGRRamio-TorrentaLHadjiprocopisAChardDTGriffinCMRashidWBarkerGJKapoorRThompsonAJMillerDHJ Neurol Neurosurg Psychiatry200475998100210.1136/jnnp.2003.021915173910015201359Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosisFisnikuLKAltmannDRCercignaniMTozerDJChardDTJacksonJSMiszkielKASchmiererKThompsonAJMillerDHMult Scler20091566867710.1177/1352458509103715304097419435751Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer studyRamio-TorrentaLSastre-GarrigaJIngleGTDaviesGRAmeenVMillerDHThompsonAJJ Neurol Neurosurg Psychiatry200677404510.1136/jnnp.2004.052316211740516361590Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matterVrenkenHGeurtsJJKnolDLvan DijkLNDattolaVJasperseBvan SchijndelRAPolmanCHCastelijnsJABarkhofFPouwelsPJRadiology200624081182010.1148/radiol.240305056916868279Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosisManfredoniaFCiccarelliOKhaleeliZTozerDJSastre-GarrigaJMillerDHThompsonAJArch Neurol20076441141510.1001/archneur.64.3.41117353385Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRIRovarisMGalloAValsasinaPBenedettiBCaputoDGhezziAMontanariESormaniMPBertolottoAMancardiGBergamaschiRMartinelliVComiGFilippiMNeuroimage2005241139114610.1016/j.neuroimage.2004.10.00615670691Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deteriorationVrenkenHPouwelsPJGeurtsJJKnolDLPolmanCHBarkhofFCastelijnsJAJ Magn Reson Imaging20062362863610.1002/jmri.2056416565955MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosisGeurtsJJReulingIEVrenkenHUitdehaagBMPolmanCHCastelijnsJABarkhofFPouwelsPJMagn Reson Med20065547848310.1002/mrm.2079216463353Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging studyKapellerPMcLeanMAGriffinCMChardDParkerGJBarkerGJThompsonAJMillerDHJ Neurol200124813113810.1007/s00415017024811284131Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosisChardDTGriffinCMMcLeanMAKapellerPKapoorRThompsonAJMillerDHBrain20021252342235210.1093/brain/awf24012244090Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAXJasperseBValsasinaPNeacsuVKnolDLDe StefanoNEnzingerCSmithSMRopeleSKortewegTGiorgioAAndersonVPolmanCHFilippiMMillerDHRovarisMBarkhofFVrenkenHJ Magn Reson Imaging20072688188510.1002/jmri.2110117896359Accurate, robust, and automated longitudinal and cross-sectional brain change analysisSmithSMZhangYJenkinsonMChenJMatthewsPMFedericoADe StefanoNNeuroimage20021747948910.1006/nimg.2002.104012482100Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matterGeYGrossmanRIUdupaJKBabbJSNyulLGKolsonDLRadiology200122060661010.1148/radiol.220300177611526256Focal thinning of the cerebral cortex in multiple sclerosisSailerMFischlBSalatDTempelmannCSchonfeldMABusaEBodammerNHeinzeHJDaleABrain20031261734174410.1093/brain/awg17512805100Cortical atrophy is relevant in multiple sclerosis at clinical onsetCalabreseMAtzoriMBernardiVMorraARomualdiCRinaldiLMcAuliffeMJBarachinoLPeriniPFischlBBattistinLGalloPJ Neurol20072541212122010.1007/s00415-006-0503-617361339Widespread cortical thinning characterizes patients with MS with mild cognitive impairmentCalabreseMRinaldiFMattisiIGrossiPFavarettoAAtzoriMBernardiVBarachinoLRomualdiCRinaldiLPeriniPGalloPNeurology20107432132810.1212/WNL.0b013e3181cbcd0320101038Relating neocortical pathology to disability progression in multiple sclerosis using MRIChenJTNarayananSCollinsDLSmithSMMatthewsPMArnoldDLNeuroimage2004231168117510.1016/j.neuroimage.2004.07.04615528116Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotypePaganiERoccaMAGalloARovarisMMartinelliVComiGFilippiMAJNR Am J Neuroradiol20052634134615709132Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal studySastre-GarrigaJIngleGTChardDTCercignaniMRamio-TorrentaLMillerDHThompsonAJBrain20051281454146010.1093/brain/awh49815817511Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disabilityRoosendaalSDBendfeldtKVrenkenHPolmanCHBorgwardtSRadueEWKapposLPelletierDHauserSLMatthewsPMBarkhofFGeurtsJJMult Scler2011Evidence of early cortical atrophy in MS: relevance to white matter changes and disabilityDe StefanoNMatthewsPMFilippiMAgostaFDe LucaMBartolozziMLGuidiLGhezziAMontanariECifelliAFedericoASmithSMNeurology2003601157116212682324Brain atrophy and lesion load in a large population of patients with multiple sclerosisTedeschiGLavorgnaLRussoPPrinsterADinacciDSavettieriGQuattroneALivreaPMessinaCReggioABresciamorraVOreficeGPacielloMBrunettiAConiglioGBonavitaSDi CostanzoABellacosaAValentinoPQuarantelliMPattiFSalemiGCammarataESimoneILSalvatoreMBonavitaVAlfanoBNeurology20056528028510.1212/01.wnl.0000168837.87351.1f16043800Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromesDaltonCMChardDTDaviesGRMiszkielKAAltmannDRFernandoKPlantGTThompsonAJMillerDHBrain20041271101110710.1093/brain/awh12614998914Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosisChardDTGriffinCMRashidWDaviesGRAltmannDRKapoorRBarkerGJThompsonAJMillerDHMult Scler20041038739110.1191/1352458504ms1050oa15327034Brain atrophy in clinically early relapsing-remitting multiple sclerosisChardDTGriffinCMParkerGJKapoorRThompsonAJMillerDHBrain200212532733710.1093/brain/awf02511844733Gray matter atrophy in multiple sclerosis: a longitudinal studyFisherELeeJCNakamuraKRudickRAAnn Neurol20086425526510.1002/ana.2143618661561Gray matter atrophy is related to long-term disability in multiple sclerosisFisnikuLKChardDTJacksonJSAndersonVMAltmannDRMiszkielKAThompsonAJMillerDHAnn Neurol20086424725410.1002/ana.2142318570297Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosisAmatoMPPortaccioEGorettiBZipoliVBattagliniMBartolozziMLStromilloMLGuidiLSiracusaGSorbiSFedericoADe StefanoNArch Neurol2007641157116110.1001/archneur.64.8.115717698706Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burdenBenedictRHWeinstock-GuttmanBFishmanISharmaJTjoaCWBakshiRArch Neurol20046122623010.1001/archneur.61.2.22614967771Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosisBenedictRHBruceJMDwyerMGAbdelrahmanNHusseinSWeinstock-GuttmanBGargNMunschauerFZivadinovRArch Neurol2006631301130610.1001/archneur.63.9.130116966509Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosisTekok-KilicABenedictRHWeinstock-GuttmanBDwyerMGCaroneDSrinivasaraghavanBYellaVAbdelrahmanNMunschauerFBakshiRZivadinovRNeuroimage2007361294130010.1016/j.neuroimage.2007.04.01717524670Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSSRudickRALeeJCNakamuraKFisherEJ Neurol Sci200928210611110.1016/j.jns.2008.11.018272644419100997Technical note: use of a double inversion recovery pulse sequence to image selectively grey or white brain matterRedpathTWSmithFWBr J Radiol1994671258126310.1259/0007-1285-67-804-12587874427Double inversion recovery imaging of the brain: initial experience and comparison with fluid attenuated inversion recovery imagingTuretschekKWunderbaldingerPBankierAAZontsichTGrafOMallekRHittmairKMagn Reson Imaging19981612713510.1016/S0730-725X(97)00254-39508269Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imagingGeurtsJJPouwelsPJUitdehaagBMPolmanCHBarkhofFCastelijnsJARadiology200523625426010.1148/radiol.236104045015987979Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 TeslaSimonBSchmidtSLukasCGiesekeJTraberFKnolDLWillinekWAGeurtsJJSchildHHWattjesMPEur Radiol2010201675168310.1007/s00330-009-1705-y288205020094887In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosisBagnatoFButmanJAGuptaSCalabreseMPezawasLOhayonJMTovar-MollFRivaMCaoMMTalagalaSLMcFarlandHFAJNR Am J Neuroradiol2006272161216717110688Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging studyCalabreseMFilippiMRovarisMBernardiVAtzoriMMattisiIFavarettoAGrossiPBarachinoLRinaldiLRomualdiCPeriniPGalloPMult Scler200915364110.1177/135245850809668618755823A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosisCalabreseMRoccaMAAtzoriMMattisiIFavarettoAPeriniPGalloPFilippiMAnn Neurol20106737638320373349Imaging distribution and frequency of cortical lesions in patients with multiple sclerosisCalabreseMBattagliniMGiorgioAAtzoriMBernardiVMattisiIGalloPDe StefanoNNeurology2010751234124010.1212/WNL.0b013e3181f5d4da20739644Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR studyCalabreseMRoccaMAAtzoriMMattisiIBernardiVFavarettoABarachinoLRomualdiCRinaldiLPeriniPGalloPFilippiMNeurology2009721330133610.1212/WNL.0b013e3181a0fee519365054Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosisCalabreseMDe StefanoNAtzoriMBernardiVMattisiIBarachinoLMorraARinaldiLRomualdiCPeriniPBattistinLGalloPArch Neurol2007641416142210.1001/archneur.64.10.141617923625Accumulation of cortical lesions in MS: relation with cognitive impairmentRoosendaalSDMoraalBPouwelsPJVrenkenHCastelijnsJABarkhofFGeurtsJJMult Scler20091570871410.1177/135245850910290719435749Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosisNelsonFDattaSGarciaNRozarioNLPerezFCutterGNarayanaPAWolinskyJSMult Scler2011Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosisCalabreseMAgostaFRinaldiFMattisiIGrossiPFavarettoAAtzoriMBernardiVBarachinoLRinaldiLPeriniPGalloPFilippiMArch Neurol2009661144115010.1001/archneurol.2009.17419752305Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI studyCalabreseMFilippiMRovarisMMattisiIBernardiVAtzoriMFavarettoABarachinoLRinaldiLRomualdiCPeriniPGalloPNeuroimage2008421324132810.1016/j.neuroimage.2008.06.02818652903Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRIGeurtsJJRoosendaalSDCalabreseMCiccarelliOAgostaFChardDTGassAHuergaEMoraalBParetoDRoccaMAWattjesMPYousryTAUitdehaagBMBarkhofFNeurology20117641842410.1212/WNL.0b013e31820a0cc421209373Post mortem verification of MS cortical lesion detection with 3D-DIRSeewannAKooiEJRoosendaalSDPouwelsPJWattjesMPvan der ValkPBarkhofFPolmanCHGeurtsJJNeurology2011Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosisSeewannAVrenkenHKooiEJvan dVKnolDLPolmanCHPouwelsPJBarkhofFGeurtsJJMult Scler20113D MPRAGE improves classification of cortical lesions in multiple sclerosisNelsonFPoonawallaAHouPWolinskyJSNarayanaPAMult Scler2008141214121910.1177/1352458508094644265024918952832Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imagingNelsonFPoonawallaAHHouPHuangFWolinskyJSNarayanaPAAJNR Am J Neuroradiol2007281645164910.3174/ajnr.A064517885241Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imagingPittDBosterAPeiWWohlebEJasneAZachariahCRRammohanKKnoppMVSchmalbrockPArch Neurol20106781281810.1001/archneurol.2010.14820625086Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 TeslaKangarluABourekasECRay-ChaudhuryARammohanKWAJNR Am J Neuroradiol20072826226617296991High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosisSchmiererKParkesHGSoPWAnSFBrandnerSOrdidgeRJYousryTAMillerDHBrain201013385886710.1093/brain/awp33520123726First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7TKolliaKMaderwaldSPutzkiNSchlamannMTheysohnJMKraffOLaddMEForstingMWankeIAJNR Am J Neuroradiol20093069970210.3174/ajnr.A143419147714High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patientsMetcalfMXuDOkudaDTCarvajalLSrinivasanRKelleyDAMukherjeePNelsonSJVigneronDBPelletierDJ Neuroimaging20102014114710.1111/j.1552-6569.2008.00338.x287460519187478In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRIMaineroCBennerTRaddingAvan derKAJensenRRosenBRKinkelRPNeurology20097394194810.1212/WNL.0b013e3181b64bf72754332196411683 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesionsTallantyreECMorganPSDixonJEAl RadaidehABrookesMJMorrisPGEvangelouNJ Magn Reson Imaging20103297197710.1002/jmri.2211520882628Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation studyBermelRAInnusMDTjoaCWBakshiRNeuroreport20031433533912634479Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry studyPrinsterAQuarantelliMOreficeGLanzilloRBrunettiAMollicaCSalvatoreEMorraVBCoppolaGVaccaGAlfanoBSalvatoreMNeuroimage20062985986710.1016/j.neuroimage.2005.08.03416203159Extensive hippocampal demyelination in multiple sclerosisGeurtsJJBoLRoosendaalSDHazesTDanielsRBarkhofFWitterMPHuitingaIvan der ValkPJ Neuropathol Exp Neurol20076681982710.1097/nen.0b013e3181461f5417805012Hypothalamic lesions in multiple sclerosisHuitingaIDe GrootCJvan dVKamphorstWTildersFJSwaabDFJ Neuropathol Exp Neurol2001601208121811764093Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesionsHuitingaIErkutZAvan BeurdenDSwaabDFAnn Neurol200455374510.1002/ana.1076614705110A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypesCeccarelliARoccaMAPaganiEColomboBMartinelliVComiGFilippiMNeuroimage20084231532210.1016/j.neuroimage.2008.04.17318501636Thalamic atrophy and cognition in multiple sclerosisHoutchensMKBenedictRHKillianyRSharmaJJaisaniZSinghBWeinstock-GuttmanBGuttmannCRBakshiRNeurology2007691213122310.1212/01.wnl.0000276992.17011.b517875909Thalamic neurodegeneration in multiple sclerosisCifelliAArridgeMJezzardPEsiriMMPalaceJMatthewsPMAnn Neurol20025265065310.1002/ana.1032612402265Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosisDaviesGRAltmannDRRashidWChardDTGriffinCMBarkerGJKapoorRThompsonAJMillerDHMult Scler20051127628110.1191/1352458505ms1166oa15957507Thalamic neurodegeneration in relapsing-remitting multiple sclerosisWylezinskaMCifelliAJezzardPPalaceJAlecciMMatthewsPMNeurology2003601949195412821738Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control studyRamasamyDPBenedictRHCoxJLFritzDAbdelrahmanNHusseinSMinagarADwyerMGZivadinovRJ Neurol Sci2009282475410.1016/j.jns.2008.12.03419201003Thalamic damage and long-term progression of disability in multiple sclerosisRoccaMAMesarosSPaganiESormaniMPComiGFilippiMRadiology201025746346910.1148/radiol.1010032620724544Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging studyFabianoAJSharmaJWeinstock-GuttmanBMunschauerFEBenedictRHZivadinovRBakshiRJ Neuroimaging20031330731414569822Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MSCaroneDABenedictRHDwyerMGCookfairDLSrinivasaraghavanBTjoaCWZivadinovRNeuroimage20062950551410.1016/j.neuroimage.2005.07.05316169253Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosisCalabreseMRinaldiFGrossiPMattisiIBernardiVFavarettoAPeriniPGalloPMult Scler2010161220122810.1177/135245851037640520670981Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosisAudoinBZaaraouiWReuterFRicoAMalikovaIConfort-GounySCozzonePJPelletierJRanjevaJPJ Neurol Neurosurg Psychiatry20108169069510.1136/jnnp.2009.18874820392976Evidence of thalamic gray matter loss in pediatric multiple sclerosisMesarosSRoccaMAAbsintaMGhezziAMilaniNMoiolaLVeggiottiPComiGFilippiMNeurology2008701107111218272867Deep gray matter atrophy in multiple sclerosis: a tensor based morphometryTaoGDattaSHeRNelsonFWolinskyJSNarayanaPAJ Neurol Sci2009282394610.1016/j.jns.2008.12.035274486719168189Localization of grey matter atrophy in early RRMS: A longitudinal studyAudoinBDaviesGRFiniskuLChardDTThompsonAJMillerDHJ Neurol20062531495150110.1007/s00415-006-0264-217093899Regional grey matter atrophy in clinically isolated syndromes at presentationHenryRGShiehMOkudaDTEvangelistaAGorno-TempiniMLPelletierDJ Neurol Neurosurg Psychiatry2008791236124410.1136/jnnp.2007.13482518469033Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry studySepulcreJSastre-GarrigaJCercignaniMIngleGTMillerDHThompsonAJArch Neurol2006631175118010.1001/archneur.63.8.117516908748MRI correlates of cognitive impairment in childhood-onset multiple sclerosisTillCGhassemiRAubert-BrocheBKerbratACollinsDLNarayananSArnoldDLDesrocherMSledJGBanwellBLNeuropsychology20112531933221534686Substantial archaeocortical atrophy and neuronal loss in multiple sclerosisPapadopoulosDDukesSPatelRNicholasRVoraAReynoldsRBrain Pathol20091923825310.1111/j.1750-3639.2008.00177.x18492094In vivo MR imaging of hippocampal lesions in multiple sclerosisRoosendaalSDMoraalBVrenkenHCastelijnsJAPouwelsPJBarkhofFGeurtsJJJ Magn Reson Imaging20082772673110.1002/jmri.2129418302199Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative studyAndersonVMFisnikuLKKhaleeliZSummersMMPennySAAltmannDRThompsonAJRonMAMillerDHMult Scler2010161083109010.1177/135245851037489320630904Regional hippocampal atrophy in multiple sclerosisSicotteNLKernKCGiesserBSArshanapalliASchultzAMontagMWangHBookheimerSYBrain20081311134114110.1093/brain/awn03018375977Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosisAudoinBAu DuongMVRanjevaJPIbarrolaDMalikovaIConfort-GounySSoulierEVioutPAli-CherifAPelletierJCozzonePJHum Brain Mapp20052421622810.1002/hbm.2008315543553Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up studyAudoinBReuterFDuongMVMalikovaIConfort-GounySCherifAACozzonePJPelletierJRanjevaJPMult Scler20081478679210.1177/135245850808936018573836fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosisMaineroCCaramiaFPozzilliCPisaniAPestalozzaIBorrielloGBozzaoLPantanoPNeuroimage20042185886710.1016/j.neuroimage.2003.10.00415006652Structural and functional MRI correlates of Stroop control in benign MSRoccaMAValsasinaPCeccarelliAAbsintaMGhezziARiccitelliGPaganiEFaliniAComiGScottiGFilippiMHum Brain Mapp20093027629010.1002/hbm.2050418041737Analysis of impairment related functional architecture in MS patients during performance of different attention tasksPennerIKRauschMKapposLOpwisKRaduEWJ Neurol200325046147210.1007/s00415-003-1025-012700913Default-mode network dysfunction and cognitive impairment in progressive MSRoccaMAValsasinaPAbsintaMRiccitelliGRodegherMEMisciPRossiPFaliniAComiGFilippiMNeurology2010741252125910.1212/WNL.0b013e3181d9ed9120404306fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volumeBobholzJARaoSMLobeckLElsingerCGleasonAKanzJDurgerianSMaasENeurology2006671640164510.1212/01.wnl.0000242885.71725.7617101897Structural and functional hippocampal changes in multiple sclerosis patients with intact memory functionRoosendaalSDHulstHEVrenkenHFeenstraHECastelijnsJAPouwelsPJBarkhofFGeurtsJJRadiology201025559560410.1148/radiol.1009143320413769Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosisHulstHESchoonheimMMRoosendaalSDPopescuVSchwerenLJvan der WerfYDVisserLHPolmanCHBarkhofFGeurtsJJHum Brain Mapp2011Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelinationTsunodaIFujinamiRSSpringer Semin Immunopathol20022410512510.1007/s00281-002-0105-z12503060Gray matter pathology in (chronic) MS: modern views on an early observationGeurtsJJStysPKMinagarAAmorSZivadinovRJ Neurol Sci2009282122010.1016/j.jns.2009.01.01819249061Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosisBoLGeurtsJJvan dVPolmanCBarkhofFArch Neurol200764768010.1001/archneur.64.1.7617210812Grey matter pathology in multiple sclerosisGeurtsJJBarkhofFLancet Neurol2008784185110.1016/S1474-4422(08)70191-118703006

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/11/153/prepub